Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT05445089

Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients

Multicenter, Randomized, Double-blind Study With Placebo to Verify the Efficacy, Safety and Tolerability of the Modified Isothymol or Carvacrol Compound Against the SARS-CoV-2 Agent in COVID-19 Patients

Sponsor: Instituto Venezolano de Investigaciones Cientificas

Conditions COVID-19 COVID-19 Acute Respiratory Distress Syndrome COVID-19 Lower Respiratory Infection COVID-19 Pneumonia COVID-19 Respiratory Infection

Interventions Carvacrol Control group

Updated 3 times since 2022 Last updated: Jul 5, 2022 Started: Aug 1, 2020 Primary completion: Nov 1, 2020 Completion: Dec 15, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05445089, this PHASE2/PHASE3 trial focuses on COVID-19 and COVID-19 Acute Respiratory Distress Syndrome and remains completed. Sponsored by Instituto Venezolano de Investigaciones Cientificas, it has been updated 3 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Sep 2022 — Jul 2024 [monthly]

Completed PHASE2_PHASE3

First recorded

Aug 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Instituto Venezolano de Investigaciones Cientificas

Data source: Instituto Venezolano de Investigaciones Cientificas

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Caracas, Venezuela